In some respects, AI is reinventing the very act of pharmaceutical research. Across leading biopharma companies, the image of the “bench scientist” is vanishing, replaced by a “Researcher 2.0” who spends more time training algorithms and curating datasets than mixing molecules. Tools like Life Science Dynamics’ IntelliCentral can now sweep through decades of clinical literature,…